Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Core Scientific (CORZZ) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Core Scientific (CORZZ) over the last 5 years, with Q3 2025 value amounting to $77.2 million.

  • Core Scientific's Cost of Revenue fell 1917.29% to $77.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.3 million, marking a year-over-year decrease of 2233.3%. This contributed to the annual value of $389.6 million for FY2024, which is 281.34% up from last year.
  • Latest data reveals that Core Scientific reported Cost of Revenue of $77.2 million as of Q3 2025, which was down 1917.29% from $73.6 million recorded in Q2 2025.
  • In the past 5 years, Core Scientific's Cost of Revenue ranged from a high of $189.6 million in Q3 2022 and a low of $39.7 million during Q1 2021
  • For the 5-year period, Core Scientific's Cost of Revenue averaged around $101.5 million, with its median value being $95.5 million (2024).
  • In the last 5 years, Core Scientific's Cost of Revenue surged by 24661.06% in 2022 and then crashed by 4859.69% in 2023.
  • Over the past 5 years, Core Scientific's Cost of Revenue (Quarter) stood at $160.4 million in 2021, then rose by 5.03% to $168.5 million in 2022, then plummeted by 39.09% to $102.6 million in 2023, then decreased by 12.15% to $90.2 million in 2024, then decreased by 14.38% to $77.2 million in 2025.
  • Its last three reported values are $77.2 million in Q3 2025, $73.6 million for Q2 2025, and $71.3 million during Q1 2025.